|View printer-friendly version|
The abstract presentation, entitled, “Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results,” will be presented as part of the Advances in Retinal Gene Therapy and Stem Cells Session on
- The poster presentation, entitled, “Transplantation of human embryonic stem cell derived retinal tissue in the subretinal space of immunodeficient rats with retinal degeneration (RD),” will be presented as part of the Animal Models for Visual Disease and Restoration Session on
April 30, 2019 between 8:45am and 10:30amEDT in Session Number 332 by Igor Nasonkin, PhD, Principal Investigator, Director of Research & Development at BioTime, Inc.(Posterboard Number: 3109 - A0500).
- The poster presentation, entitled, “Evaluation of selected Human Embryonic Stem Cell Lines for differentiation to three-dimensional retinal tissue (organoids) for cell therapies of retinal degenerative conditions,” will be presented as part of the Stem Cells and Retinal Organoids: Disease Modeling Session on
April 30, 2019between 8:45amand 10:30amEDT in Session Number 323 by Ratnesh Singh, PhD, Senior Scientist at BioTime, Inc.(Posterboard Number: 2873 - A0044).
OpRegen is a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry AMD, the leading cause of adult blindness in the developed world. OpRegenconsists of a suspension of RPE cells delivered subretinally as an intraocular injection. RPE cells are essential components of the back lining of the retina and function to help nourish the retina including photoreceptors. OpRegen has been granted Fast Track designation from the
BioTime Inc. IR
Ioana C. Hone
Solebury Trout IR
Gitanjali Jain Ogawa